Cover Image
市場調查報告書

激素敏感性前列腺癌:全球臨床實驗趨勢

Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 298504
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
激素敏感性前列腺癌:全球臨床實驗趨勢 Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月22日 內容資訊: 英文 76 Pages
簡介

本報告提供激素敏感性前列腺癌治療藥相關臨床實驗之最新趨勢分析,提供您疾病概要,主要國家的臨床實驗狀況,各地區·各階段的進展,受驗者的募集情況,有潛力的贊助商,並彙整各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要國家的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上激素敏感性前列腺癌的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上激素敏感性前列腺癌的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

激素敏感性前列腺癌治療藥臨床實驗主要的參與企業

有潛力的藥劑

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4595CTIDB

GlobalData's clinical trial report, "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Hormone-Sensitive Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Hormone-Sensitive Prostate Cancer to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Hormone-Sensitive Prostate Cancer to Oncology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Hormone-Sensitive Prostate Cancer 31
  • Sep 08, 2017: New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer 31
  • Sep 01, 2017: Bayer to Present Abstract on Darolutamide at ESMO 2017 Congress 32
  • Clinical Trial Profile Snapshots 33

Appendix 73

  • Abbreviations 73
  • Definitions 73
  • Research Methodology 74
  • Secondary Research 74
  • About GlobalData 75
  • Contact Us 75
  • Disclaimer 75
  • Source 76

List of Tables

List of Tables

  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
  • Proportion of Hormone-Sensitive Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Hormone-Sensitive Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hormone-Sensitive Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hormone-Sensitive Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Hormone-Sensitive Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hormone-Sensitive Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hormone-Sensitive Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
  • Proportion of Hormone-Sensitive Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Hormone-Sensitive Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hormone-Sensitive Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hormone-Sensitive Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Hormone-Sensitive Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hormone-Sensitive Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Hormone-Sensitive Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hormone-Sensitive Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 74
Back to Top